This represents an important limitation to its efficiency as LM develops at late stages of NSCLC when patients have already acquired resistance to EGFR-TKIs.8,9 This highlights the urgent need to uncover alternative therapies, especially for the primary-site disease. This evidence concerns the gene EGFR and non-small cell lung carcinoma.